Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:18:41.634Z.
Calculation as of: 2026-10-06T19:18:41.634Z.
Quote observation: 2026-10-06T19:13:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c6190991d8493eebdba731817b981db063e7ae28b86b69413d904cae69ffb2ef
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$49.36M
Price/FCF Ratio
N/A
TTM Avg
99.30
3Y Avg
99.30
5Y Avg
93.30
Market Cap
$49.06M
Price/FCF Ratio
N/A
TTM Avg
62.26
3Y Avg
60.70
5Y Avg
63.54
Market Cap
$48.99M
Price/FCF Ratio
N/A
TTM Avg
13.23
3Y Avg
14.22
5Y Avg
14.22
Market Cap
$50.44M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TELA Bio, Inc. (TELA) | $49.21M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.36M | N/A | 99.30 | 99.30 | 93.30 |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.06M | N/A | 62.26 | 60.70 | 63.54 |
| Apollomics, Inc. (APLM)vs › | $49.50M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $48.99M | N/A | 13.23 | 14.22 | 14.22 |
| INmune Bio, Inc. (INMB)vs › | $49.58M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $50.44M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $50.86M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.37M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $47.64M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
